Gain Therapeutics Stock Analysis
GANX Stock | USD 1.59 0.02 1.24% |
Gain Therapeutics is undervalued with Real Value of 3.16 and Target Price of 8.0. The main objective of Gain Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Gain Therapeutics is worth, separate from its market price. There are two main types of Gain Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Gain Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Gain Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Gain Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Gain Stock Analysis Notes
The company recorded a loss per share of 0.83. Gain Therapeutics had not issued any dividends in recent years. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. The company was founded in 2017 and is based in Bethesda, Maryland. Gain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. To learn more about Gain Therapeutics call LLM IUR at 301 500 1556 or check out https://gaintherapeutics.com.Gain Therapeutics Investment Alerts
Gain Therapeutics generated a negative expected return over the last 90 days | |
Gain Therapeutics may become a speculative penny stock | |
Gain Therapeutics has high historical volatility and very poor performance | |
Net Loss for the year was (20.41 M) with loss before overhead, payroll, taxes, and interest of (10.4 M). | |
Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Gain Therapeutics has a frail financial position based on the latest SEC disclosures | |
Latest headline from thelincolnianonline.com: Gain Therapeutics, Inc. Receives 8.20 Average Price Target from Analysts |
Gain Therapeutics Upcoming and Recent Events
Earnings reports are used by Gain Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
28th of March 2024 Upcoming Quarterly Report | View | |
10th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
28th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Gain Largest EPS Surprises
Earnings surprises can significantly impact Gain Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2025-05-12 | 2025-03-31 | -0.18 | -0.16 | 0.02 | 11 | ||
2024-11-12 | 2024-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2024-03-26 | 2023-12-31 | -0.32 | -0.36 | -0.04 | 12 |
Gain Stock Institutional Investors
Shares | Cambridge Invest Research Advisors, Inc. | 2025-03-31 | 59.5 K | Kovitz Investment Group Partners, Llc | 2025-03-31 | 47.6 K | Ubs Group Ag | 2025-03-31 | 43.4 K | Springbok Capital Management, Llc | 2025-03-31 | 35.8 K | Bridgeway Capital Management, Llc | 2025-03-31 | 30 K | Quadrature Capital Llp | 2025-03-31 | 20.2 K | Citadel Advisors Llc | 2025-03-31 | 19 K | Benedict Financial Advisors, Inc. | 2025-03-31 | 18 K | Sandhill Capital Partners Llc | 2025-03-31 | 15.4 K | Jones Financial Companies Lllp | 2025-03-31 | 427.7 K | Geode Capital Management, Llc | 2025-03-31 | 282.2 K |
Gain Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 47.31 M.Gain Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.70) | (1.79) | |
Return On Capital Employed | (2.48) | (2.35) | |
Return On Assets | (1.68) | (1.77) | |
Return On Equity | (2.78) | (2.64) |
Management Efficiency
Gain Therapeutics has return on total asset (ROA) of (0.971) % which means that it has lost $0.971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9022) %, meaning that it created substantial loss on money invested by shareholders. Gain Therapeutics' management efficiency ratios could be used to measure how well Gain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.79 in 2025. Return On Capital Employed is likely to rise to -2.35 in 2025. At this time, Gain Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 15.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 12.8 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.32 | 0.30 | |
Tangible Book Value Per Share | 0.31 | 0.30 | |
Enterprise Value Over EBITDA | (2.01) | (2.11) | |
Price Book Value Ratio | 6.73 | 7.07 | |
Enterprise Value Multiple | (2.01) | (2.11) | |
Price Fair Value | 6.73 | 7.07 | |
Enterprise Value | 39.7 M | 70.5 M |
Leadership effectiveness at Gain Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 22nd of July, Gain Therapeutics retains the Risk Adjusted Performance of (0.02), standard deviation of 4.61, and Market Risk Adjusted Performance of 0.6307. Gain Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Gain Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Gain Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Gain Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
Gain Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gain Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gain Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gain Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gain Therapeutics Outstanding Bonds
Gain Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gain Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gain bonds can be classified according to their maturity, which is the date when Gain Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
HLNLN 3625 24 MAR 32 Corp BondUS36264FAM32 | View | |
HLNLN 3375 24 MAR 29 Corp BondUS36264FAL58 | View | |
HLNLN 4 24 MAR 52 Corp BondUS36264FAN15 | View | |
HLNLN 3375 24 MAR 27 Corp BondUS36264FAK75 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
US36261NAA54 Corp BondUS36261NAA54 | View |
Gain Therapeutics Predictive Daily Indicators
Gain Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gain Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Gain Therapeutics Forecast Models
Gain Therapeutics' time-series forecasting models are one of many Gain Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gain Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Gain Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Gain Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Gain shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Gain Therapeutics. By using and applying Gain Stock analysis, traders can create a robust methodology for identifying Gain entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (462.42) | (439.30) | |
Operating Profit Margin | (463.77) | (440.59) | |
Net Loss | (464.07) | (440.87) | |
Gross Profit Margin | (0.41) | (0.43) |
Current Gain Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Gain analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Gain analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
8.0 | Strong Buy | 7 | Odds |
Most Gain analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Gain stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Gain Therapeutics, talking to its executives and customers, or listening to Gain conference calls.
Gain Stock Analysis Indicators
Gain Therapeutics stock analysis indicators help investors evaluate how Gain Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Gain Therapeutics shares will generate the highest return on investment. By understating and applying Gain Therapeutics stock analysis, traders can identify Gain Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 11.8 M | |
Long Term Debt | 328.3 K | |
Common Stock Shares Outstanding | 22.9 M | |
Total Stockholder Equity | 7.3 M | |
Total Cashflows From Investing Activities | 5 M | |
Tax Provision | 536.8 K | |
Property Plant And Equipment Net | 323.3 K | |
Cash And Short Term Investments | 10.4 M | |
Cash | 10.4 M | |
Accounts Payable | 946.3 K | |
Net Debt | -9.7 M | |
50 Day M A | 1.8146 | |
Total Current Liabilities | 3.9 M | |
Other Operating Expenses | -20.4 M | |
Non Current Assets Total | 521.4 K | |
Non Currrent Assets Other | 63.8 K | |
Stock Based Compensation | 2.4 M |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.